Jazz Pharmaceuticals, shared on LinkedIn:
“We’re pleased to announce the successful completion of our acquisition of Actio Biosciences, Inc., further strengthening our neuroscience portfolio and expanding our work in rare epilepsies.
We are excited to welcome our new Actio colleagues to Jazz. By bringing together complementary expertise in precision medicine and drug development, we have an opportunity to advance important work for the KCNT1+ developmental and epileptic encephalopathies (DEE) community, where significant unmet need remains and new treatment options are urgently needed.”
Other articles about Jazz Pharmaceuticals on OncoDaily.